Challenges in HIV Vaccine phase III Community-based Trial in Thailand. AIDS Vaccine 2007 Conference,

Similar documents
Exploratory Age-stratified Analysis of Risk-taking Behaviors and Trial Participation Outcomes in the Thai Phase III HIV Vaccine Trial

ALVAC -HIV and AIDSVAX B/E Prime-Boost HIV-1 Preventive Vaccine Regimen. Results of the Thai HIV Vaccine Trial, RV144

HIV Vaccine. 15 September 2016 นพ.นคร เปรมศร ผ อ านวยการส าน กงาน โครงการศ กษาว คซ นเอดส ทดลอง

HIV 1 Preventive Vaccine Regimen. Community based Trial in Thailand V 144. for the MOPH TAVEG Collaboration

30 Years of Thai US Collaboration Charles H. Hoke, Jr., MD

Planned Vaccine Trials to Follow-up on RV 144. Merlin Robb, MD Deputy Director for Clinical Research MHRP

Vaccine Trial Centre. Established in1984 Funded by WHO on Control of Diarrhea Diseases Full operation in1986

Group 2: 2: Ethical, Ethical, Regulatory, Regulatory, & Community Issues

Current State of HIV Vaccine Development

Preparations for HIV Vaccine Research at Zambia-Emory HIV Research Project (ZEHRP)

Questions and answers: HVTN 110 vaccine study

Critical interactions between Global Fund-supported programmes and health systems: a case study in Thailand

Thailand National Strategy on STIs Prevention and Control,

HIV Drug Resistance Surveillance and Monitoring in the Southeast Asia Region

SAFE MALE CIRCUMCISION UPDATE MEETING June 2009 NAIROBI KENYA BOTSWANA SAFE MALE CIRCUMCISION ADDITIONAL STRATEGY FOR HIV PREVENTION

Zero HIV infections Zero HIV deaths Zero HIV stigma. Stephanie Cohen, MD, MPH on behalf of the Getting to Zero Consortium

Thailand Na*onal CAB AVAC Partners Forum 25 th March 2015

UNGASS Declaration of Commitment on HIV/AIDS: Core Indicators revision

Experiences with Live Attenuated Avian Influenza Vaccine Trials in Thailand

Transitions sanitaires en Thaïlande Health Transitions in Thailand

HVTN 505 Study HIV Vaccine Candidate Not Effective

GAVI partners Forum, Dar es Salaam, Tanzania December 5-7, 2012

Differentiated Care for Antiretroviral Therapy for Key Populations: Case Examples from the LINKAGES Project

Modernizing Public Health Infectious Disease Programs: PrEP and TasP

Dengue Haemorrhagic Fever in Thailand

The Process of Policy Implementation: the Policy of HIV/AIDS Prevention in Youth Groups in Thailand

HIV-1 Vaccine Development Clinical Trials and Public Health Benefits Chaiyos Kunanusont HIV/AIDS Adviser United Nations Population Fund

COMMUNITY-BASED TBHIV CASE-FINDING KENYAN EXPERIENCE

PROGRESS ON IMPLEMENTATION OF THE 3Is IN SOUTH AFRICA. Yogan Pillay Deputy Director General Strategic Health Programmes South Africa

THE MULTI-SECTORAL APPROACH TO AIDS CONTROL IN UGANDA EXECUTIVE SUMMARY

Update on PrEP progress: WHO/UNAIDS challenges and actions

Women s Inclusion in HIV Clinical Research: Challenges and Successes

HIV TRENDS UNIVERSAL ACCESS TO HIV TREATMENT IN KENYA

The Feasibility of HIV Prevention Cohort Studies among Men who have Sex with Men (MSM) in sub-saharan Africa

Progress reports on selected Regional Committee resolutions:

Ending mother to child transmission through community action. Ngashi Ngongo, MD, MPH Senior Health Advisor UNICEF New York

Community Health Workers (CHWs) in HIV Services: Insights from Virginia. November 16, 2017

Announcement for a Principal Recipient for HIV and TB program Funded by the Global Fund to Fight AIDS, TB and Malaria for

HIV/AIDS in Practice. An Expert Commentary with Nelson Michael, MD, PhD. A Clinical Context Report

Ebola Prevention Vaccine Evaluation in Sierra Leone

A FAITH MEETS HEALTH PARTNERSHIP

The estimated prevalence of cases in Jordan is 0.02%. These estimates are based on several existing factors outlined below. The fact that these

Surveillance, Thailand

H1N1 Vaccine Based on CDCs ACIP Meeting, July 29, 2009

WHO HIV Drug Resistance Strategy

The History of HIV Vaccine Development

Polio model in Ethiopia

Response to HIV LOGISTICAL AND OTHER PERSPECTIVES

Jennifer A. Wagman, MHS, PhD Student Johns Hopkins Bloomberg School of Public Health 12 October 2011

Regional Collaboration to Optimize the Cascade: The Northwestern Public Health CFAR Consortium

Reintroducing the IUD in Kenya

Asia is large and diverse. HIV/AIDS: Regional and Thailand. The Asian HIV Epidemic. Praphan Phanuphak, M.D., Ph.D.

GOVERNMENT OF SIERRA LEONE NATIONAL HIV/AIDS POLICY

Science and community in the response to HIV, STIs and co-infections in Asia and the Pacific: Panel Discussion on PrEP & STIs

HIV Drug Resistance (HIVDR)

Fulton County Board of Health Strategy to End the HIV Epidemic in Fulton County

Annex A: Impact, Outcome and Coverage Indicators (including Glossary of Terms)

Building Long-term Capacity for HIV/AIDS in Africa: S-S and Regional Strategies

IHI South Africa Quarterly Report

Collaboration among TB/HIV CSOs and HIV and TB programs in Ukraine

Making Dengue a Vaccine Preventable Disease

Sharing the Results from Asia. World Bank, June 2008

Technical guidance for Round 9 Global Fund HIV proposals

Good Participatory Practice guidelines

Pandemic Influenza Preparedness and Response

Update of The National Vaccine Plan

HIV vaccine research and development

National AIDS Control Program (NACP)

State of the Network. TREAT Asia Network Annual Meeting Chiang Mai, Thailand October 2008

A Randomized Placebo-Controlled Trial of Citalopram for Anxiety Disorders Following Traumatic Brain Injury

HIV PREVENTION RESEARCH UNIT

Guidelines for scaling-up the 100% condom use programme:

HARM REDUCTION IN ASIA. Adeeba Kamarulzaman University of Malaya, Kuala Lumpur

Cross-cutting HSS (Health Systems Strengthening): Experience from WPRO

Responding to Vaccine Safety Events

Chiang Mai University/Johns Hopkins University HIV/AIDS Research on VCT

SECTOR ASSESMENT (SUMMARY): HEALTH

Trends in Vaccine Presentations and Packaging

Outline. Successful Integration of Hepatitis Vaccination Services into Programs for High-Risk Adults An Update of State-Based Programs

Reasons for vaccine acceptance: parents and girls perspectives

The Global Fund & UNICEF Partnership

Management of Antiretroviral Treatment (ART) and Long-Term Adherence to ART

Accelerating Children s HIV Treatment (ACT): Rationale, Progress & Challenges

Prepped 4 PrEP! KP-led services in Vietnam. Dr. Kimberly Green, PATH

Also, we were unable to answer all of your questions and are in the process of finding answers to those remaining.

Improving Health Outcomes Through NCD Prevention. Webinar February 21, 2018

SUMMARY REPORT: Africa Sub-Regional Lusophone HIV and AIDS Capacity-Building Workshop

DRAFT UNICEF PROCUREMENT OF HIV/AIDS-RELATED SUPPLIES AND SERVICES

ASEAN Activities on Increasing Access to ARV and HIV Related Supplies

Where are we going after effectiveness studies?

The National Infrastructure for Hepatitis C: Is There Anyone Home? December 21, 2015

The findings of the research study are as follows:

OHTN Quarterly Report: Q2 July 1 Sept 30, STRATEGIC DIRECTION ONE: Gather and Analyze Data on the HIV Epidemic and HIV Programs and Services

SASKATCHEWAN S HIV STRATEGY UPDATE

HPV & CERVICAL CANCER POLICY & LEGISLATIVE TOOLKIT, 3 RD EDITION

GOAL1 GOAL 2 GOAL 3 GOAL 4

GEORGIA STATEWIDE MSM STRATEGIC PLAN

Charting a Course for a Tobacco-Free Campus

A PAPER ON; EMPOWERMENT LEARNING STRATEGIES ON HIV/AIDS PREVENTION: THE CASE OF UGANDA

An aggressive approach for measles outbreak among adolescents in Barranquilla, Colombia, 2011

Transcription:

Challenges in HIV Vaccine phase III Community-based Trial in Thailand AIDS Vaccine 2007 Conference, 20-23 Aug. 2007 Dr. Supachai Rerks-Ngarm Principal Investigator, RV148/144 Department of Disease Control Ministry of Public Health, Thailand 1

Thailand Total population: 60,617,200 - Male: 29,850,200 - Female: 30,767,000 M:F ratio = 0.97:1 Rural 80% Buddhist > 95% Literacy >95% Strong NGOs & CBOs Health care infrastructure: Regional/Provincial hospital @ provincial level 10-12 District hospitals in each province 10-15 Health centers in each district 10-15 VHV in each sub-district 10-15 HH per VHV 2

National Plan for HIV/AIDS Vaccine Development Developed by Thai MOPH and research scientists with GPA/WHO collaboration Approved by NAC and launched in 1993 placing HIV vaccine research and development on the fast tract Aimed at research and development of safe, effective, affordable and accessible HIV vaccines for the Thai people at the earliest possible date 3

Challenges: Pre trial Study Site Selection Protocol Development & Review Resources Trial ongoing Community Engagement Retaining Volunteers Post trial Communication of Trial Results 4

Study Sites Selection: Chon Buri and Rayong Provinces Top five high prevalence provinces for military recruits 3.7-7.8% prevalence among ANC attendees during 1990s 3.9-4.8% prevalence and 0.68/100PYs incidence in community cohorts 5

North Northeast Chon Buri Province Phan Thong Central Sri Racha Bang Lamung Ban Khai Sattahip South Rayong Province Ban Chang Mueang Klaeng 6

Screening Site 40 health centers & 7 district hospitals in 8 districts Clinical Site 7 district hospitals and 1 STD clinic 7

Protocol Development: Protocol Drafting Committee Sponsors Manufacturers Local collaborators Consultations Local: NGO & CBO representatives International: WHO/UNAIDS 8

Protocol Review: Local MOPH-EC National AIDS Committee-Scientific Subcommittee Royal Thai Army-IRB Mahidol University-IRB Thai FDA Overseas US-HSRRB WRAIR-Scientific review US-NIH-AVRWG US-FDA-VRBPAC 9

Study Staff Clin. Research Co.s: #40 Pharmacy Nurses: #16 Research Assistants: #24 Training MOPH staff: -Core staffs-#15 -Community outreach team-#200 -Counselors-#96+94 -Hth. Center Officials-#80+ -Nurse coordinators-#16 -Site physicians-#16 Good Clinical Practice Counseling Standard Operating Procedures Emergency Response Record Keeping Vaccinology 10

GCP Training ACLS Training Communications Workshop 11

Laboratories: HIV serology Hematology & Flow cytometry Molecular lab. Accredited by American College of Pathologists Arm Forces Research Institute of Medical Science, Royal Thai Army 12

Data management unit -Secondary data base-vax003 -Primary data base for phase III trial Faculty of Tropical Medicine, Mahidol University 13

Specimen processing & storage 414,720 vials serum 64,150 PBMC (>99% processed < 6 hrs) Maintain Records & Specimen for >10 yrs 2 rounds samples runs Passed stringent shipment validity standards Health Promotion Center in Chol Buri, Department of Health 14

Vaccine storage & distribution center >140,000 vials of priming vaccine & placebo with same amount of diluents >70,000 vials of boosting vaccine & placebo Covering 8 clinical sites in the 2 provinces EPI Cold room in Chon Buri 15

Challenges in Community Engagement: Multilayered Community Structure Health staff Trial staff Volunteers neighbors Volunteers families Volunteers Negative Attitude and Misunderstanding Guinea pig idea Vaccine may cause HIV infection HIV challenge dose at the last injection 16

Community Engagement Activities Phasing Preparation Screening and Enrolment Retention Preparing for Results Informed local officials in Chon Buri and Rayong Provinces HIV/AIDS Awareness HIV Vaccine Education Community Health Forum & CAB* Sept. Volunteer/Community Networking 2002 2003 2004 2005 2006 2007 2008 2009 2010 Screening Immunization Follow-up Data Analysis (1 year) *CAB = Community Advisory Board 17

Challenges in Retaining the Volunteers: Long duration between appointments Family and neighbor influences Inconvenient appointment date/time Long waiting time Missed appointment due to mobility 18

Strategies to improve retention: Clinical Service Service area Team building Service behavior improvement Provider based service Volunteer relation activities Convenience clinics in Bangkok Extended clinic hours Community Engagement Health Forum Volunteer Network Community Network Community Advisory Board Tracking Local Tracking Team District Retention and Tracking Team Special Tracking Team Communication Plans Internal communication External communication: volunteers / community 19

Community Health Forum Volunteer Club Meeting Please visit our poster P06-08 20

Challenges in Communicating Trial Results: Interim Analysis Co-primary end-point Viral-load effect Community Expectations Likelihood for vaccinating placebo recipients Likelihood for vaccine licensing Likelihood for vaccine at affordable price 21

Conclusions: HIV vaccine trials require staff, infrastructure, community engagement, as well as. National support & Political commitment Long term development among multidisciplinary institutions Ability to work jointly among multi-sectoral organizations Existing health service system in shortening the preparatory processes for trial infrastructure and manpower Strong NGOs and community organization support 22

Acknowledgements Faculty of Tropical Medicine, Mahidol University Royal Thai Army Ministry of Public Health, Thailand US NIH/WRAIR/Henry M. Jackson Foundation sanofi pasteur/ VaxGen Inc. Volunteers of the several studies associated with this trial Community members in Chon Buri & Rayong provinces 23

Thank You 24